Evidence map›Paper›PMID 38671021›Full record

ArticleScientific reports2024

Comprehensiveness cuproptosis related genes study for prognosis and medication sensitiveness across cancers, and validation in prostate cancer.

Longfei Yang, Yifan Tang, Yuwei Zhang, Yang Wang, Peng Jiang, Fengping Liu, Ninghan Feng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Longfei YangMedical School of Nantong University, Nantong, 226001, China.
Yifan TangDepartment of Urology, Jiangnan University Medical Center, 68 Zhongshan Road, Wuxi, 214002, Jiangsu, China.
Yuwei ZhangMedical School of Nantong University, Nantong, 226001, China.
Yang WangDepartment of Urology, Jiangnan University Medical Center, 68 Zhongshan Road, Wuxi, 214002, Jiangsu, China.
Peng JiangDepartment of Urology, Jiangnan University Medical Center, 68 Zhongshan Road, Wuxi, 214002, Jiangsu, China.
Fengping LiuDepartment of Urology, Jiangnan University Medical Center, 68 Zhongshan Road, Wuxi, 214002, Jiangsu, China. liulaoshiyc@jiangnan.edu.cn.
Ninghan FengMedical School of Nantong University, Nantong, 226001, China. n.feng@jiangnan.edu.cn.
Jiangnan University · CNNanjing Medical University · CNWuxi Taihu Hospital · CN

Funding

Major Project of Jiangsu Commission of Health: Basic research and clinical application of biomarkers for early diagnosis of prostate cancer ZD2021002Major Project of Wuxi Commission of Health: To investigate the characteristics of urinary microecological diversity in patients with renal cell carcinoma and the effect of functional bacteria in situ on the expression of short chain fatty acids Z202103Wuxi "key medical discipline construction" Municipal Clinical Medical Center Project LCZX2021003Wuxi Taihu Lake Talent Plan, Leading Talents in Medical and Health Profession Project: Research and application of early screening and accurate diagnosis and treatment of prostate cancer THRCJH20200104Wuxi Taihu Talent Plan, Team in Medical and Health High-level Talents Project : Basic and clinical study of urothelial carcinoma of upper urinary tract THRCJH20200406
6 · The paper itself

Abstract

Cuproptosis-related genes (CRGs) are important for tumor development. However, the functions of CRGs across cancers remain obscure. We performed a pan-cancer investigation to reveal the roles of CRGs across cancers. In an analysis of 26 cancers, 12 CRGs were differentially expressed, and those CRGs were found to have prognostic value across different cancer types. The expression of CRGs exhibited varied among tumors of 6 immune subtypes and were significantly correlated with the 16 sensitivities of drugs. The expression of CRGs were highly correlated with immunological subtype and tumor microenvironment (TME) of prostate cancer. We also established CRGs-related prognostic signatures that closely correlated with prognosis and drug sensitivity of prostate cancer patients. Single-cell RNA-seq revealed that several CRGs were enriched in the cancer cells. Finally, an in vitro experiment showed that elesclomol, a cuproptosis inducer, targets ferredoxin 1 and suppress cell viability in prostate cancer cells. In conclusion, we carried out a comprehensive investigation for determining CRGs in differential expression, prognosis, immunological subtype, TME, and cancer treatment sensitivity across 26 malignancies; and validated the results in prostate cancer. Our research improves pan-cancer knowledge of CRGs and identifies more effective immunotherapy strategies.

Indexed as

Gene Expression Regulation, NeoplasticProstatic NeoplasmsTumor MicroenvironmentBiomarkers, TumorCell Line, TumorDrug Resistance, NeoplasmGene Expression ProfilingHumansMalePrognosisBiomarkers, TumorCuproptosis-related genesDrug sensitivityPan-cancer analysisPrognosisTumor microenvironment

Identifiers

PMID38671021
PMCPMC11053037
OpenAlexW4395669084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.